Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox® 400 mg And Miosan® 10 mg) in Postoperative Pain Control After Impacted Third Molar Extraction

NCT03127592 is registered in ClinicalTrials.gov with Apsen Farmaceutica S.A. as lead sponsor.

NCT NCT03127592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03127592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox® 400 mg And Miosan® 10 mg) in Postoperative Pain Control After Impacted Third Molar Extraction
Lead sponsor
Apsen Farmaceutica S.A.
Phase
Phase 3
Overall status
Terminated
Start date
October 5, 2020
Completion date
July 26, 2022
Enrollment
140 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain, acute